1. Home
  2. |Insights
  3. |This Year in Trade - Fall Update

This Year in Trade - Fall Update

Webinar | 10.08.15, 8:00 AM EDT - 9:00 AM EDT

Please click here for a copy of the presentation.

As we discussed in our first This Year in Trade webinar earlier this year, as globalization pushes forward, the potential rewards – from trade, from expansion, from partnerships – have multiplied along with the risks. As a result, companies doing business around the world are facing a variety of important issues affecting their bottom line, including sanctions, export controls, customs, and many others. On Thursday, October 8, 2015 at 12:00 pm Eastern, our Crowell & Moring team will follow up on our February 2015 predictions of the key trade issues to watch globally for 2015 and into 2016.

Our primary areas of discussion will include:

  • Economic Sanctions
  • Anti-money Laundering and Foreign Corrupt Practices Act
  • Export Controls
  • Free Trade Agreements
  • Customs
  • Antidumping
  • Cross-border Issues in Government Contracting
  • EU Trade Issues

Presenters include members of our international trade and white collar teams based in Washington, D.C., New York, and Brussels as well as a representative from our affiliated trade policy team from C&M International. We hope you can join us for this webinar.

For more information, please visit these areas: Corporate and Transactional, Anti-Money Laundering (AML), Committee on Foreign Investment in the United States (CFIUS), Export Controls, Economic Sanctions, Trade Remedies: Antidumping and Countervailing Duties, WTO, FTAs and Market Access, White Collar and Regulatory Enforcement, Litigation and Trial, Product Risk Management, Crowell Global Advisors, International Trade

Participants

Insights

Webinar | 02.25.25

First 100 Days: Navigating New Frontiers: Life Sciences in the Trump Era

Please join us for a post-Election webinar with the heads of our Government Affairs group who will address the myriad of areas in the Life Sciences industry that will likely be impacted by the new administration, including FDA, NIH, drug pricing, imports, and exports.

View All Insights